• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

Achillion Shareholders Approve Agreement to be Acquired By Alexion

Share:

December 23, 2019

Achillion Pharmaceuticals, a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement-mediated diseases, announced that its shareholders have approved the acquisition of Achillion by Alexion Pharmaceuticals.

Achillion continues to expect the transaction to close in the first half of 2020, subject to expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”). Alexion and Achillion have not yet submitted their filings under the HSR Act, and currently anticipate doing so in January 2020.

“Today’s results represent an important milestone in completing our transaction with Alexion and becoming better positioned to more quickly bring new, innovative and life-changing drugs to market,” said Joe Truitt, President and Chief Executive Officer at Achillion. “We appreciate the support of our shareholders, employees and partners, and we look forward to continuing to work with Alexion toward closing the transaction and achieving the anticipated benefits on behalf of patients and their families.”

At the December 19, 2019 special meeting of shareholders (the “Special Meeting”), Achillion’s shareholders voted to approve and adopt the Merger Agreement. Of the shares voted, approximately 99 percent voted to approve and adopt the Merger Agreement. The final vote results will be reported in a Current Report on Form 8-K filed with the Securities and Exchange Commission.

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

Under the terms of the agreement, which was announced on October 16, 2019, Alexion will acquire Achillion for an initial consideration of approximately $930 million, or $6.30 per share in cash for each share of Achillion common stock.

The transaction includes the potential for additional consideration in the form of non-tradeable contingent value rights (CVRs), which will be paid to Achillion shareholders if certain clinical and regulatory milestones are achieved within specified periods. These include $1.00 per share for the U.S. FDA approval of danicopan and $1.00 per share for ACH-5228 Phase 3 initiation.

Source: Pharmaceutical

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • COVID-19: What it Means to American Healthcare: Trends, Impacts, Predictions, and the Road AheadCOVID-19: What it Means to American Healthcare: Trends, Impacts, Predictions, and the Road Ahead
  • Surterra Wellness Closes Acquisition of New England Treatment AccessSurterra Wellness Closes Acquisition of New England Treatment Access
  • Biocytogen Announces Collaboration with Fineimmune to Develop TCR-Mimic Antibody-Based Cell TherapyBiocytogen Announces Collaboration with Fineimmune to Develop TCR-Mimic Antibody-Based Cell Therapy
  • 18 Healthcare Augmented Reality and Virtual Reality Companies to Watch18 Healthcare Augmented Reality and Virtual Reality Companies to Watch
  • InsightRX Lands $10M For Precision Medicine Dosing At The Point Of Care PlatformInsightRX Lands $10M For Precision Medicine Dosing At The Point Of Care Platform
  • Intelerad & DiA Imaging Analysis Partner to Empower Echocardiography Labs with AIIntelerad & DiA Imaging Analysis Partner to Empower Echocardiography Labs with AI
  • Health in Motion Network, Updox Integrate to Improve Pharmacy Care Amid COVID-19 PandemicHealth in Motion Network, Updox Integrate to Improve Pharmacy Care Amid COVID-19 Pandemic
  • Japanese Flu Drug Appears ‘Effective’ in Coronavirus TreatmentJapanese Flu Drug Appears ‘Effective’ in Coronavirus Treatment

Trending This Week

  • Denials Management Named Most Time-Consuming Task in RCM
  • Why Adopting Value-Based Care Models for Autism Care Is Imperative
  • Why AI-Driven Cancer Screening Will Soon Become Standard of Care
  • Bioventus Completes Divestiture of its Wound Business
  • Enzo Biochem Reports Significant Progress Toward Completing the Clinical Lab Asset Sale
  • eMolecules Acquires Specs Compound Handling B.V.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications